Mechanisms controlling vascular tone in pulmonary arterial hypertension: Implications for vasodilator therapy

Pharmacology

Volumn 79, Issue 2, 2007, Pages 65-75

  Cogolludo, Angel ^a   Moreno, Laura ^a   Villamor, Eduardo ^b  

^a SCHOOL OF MEDICINE   (Spain)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

KV channels; Protein kinase C; Pulmonary arterial hypertension; Rho kinase; Signaling pathways; Vascular tone

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BERAPROST; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; FASUDIL; FORSKOLIN; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO KINASE INHIBITOR; SILDENAFIL; THROMBOXANE A2; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL SURFACE; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; CALCIUM CHANNELS, L-TYPE; CYCLIC AMP; CYCLIC GMP; HUMANS; HYPERTENSION, PULMONARY; LUNG; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; POTASSIUM CHANNELS; PROTEIN KINASE C; PULMONARY CIRCULATION; RHO GTP-BINDING PROTEINS; VASOCONSTRICTION;

EID: 34147137194     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097754     Document Type: Review

References (53)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
2. Hyvelin JM, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P: Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97:185-191.
3. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
4. Barnes PJ, Liu SF: Regulation of pulmonary vascular tone. Pharmacol Rev 1995;47:87-131.
5. 2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004;95:496-505.
6. Ward JP, Knock GA, Snetkov VA, Aaronson PI: Protein kinases in vascular smooth muscle tone - role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol Ther 2004;104:207-231.
7. Damron DS, Nadim HS, Hong SJ, Darvish A, Murray PA: Intracellular translocation of PKC isoforms in canine pulmonary artery smooth muscle cells by ANG II. Am J Physiol 1998;274:L278-L288.
8. V1.5 channel internalization. Circ Res 2006;98:931-938.
9. + channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc Res 2005;66:84-93.
10. Salamanca DA, Khalil RA: Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol 2005;70:1537-1547.
11. + channels and pulmonary vasoconstriction: role of protein kinase Cζ. Circ Res 2003;93:656-663.
12. Littler CM, Wehling CA, Wick MJ, Fagan KA, Cool CD, Messing RO, Dempsey EC: Divergent contractile and structural responses of the murine PKC-ε null pulmonary circulation to chronic hypoxia. Am J Physiol 2005;289:L1083-L1093.
13. Loirand G, Guerin P, Pacaud P: Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-334.
14. 2+ sensitivity of smooth muscle and non-muscle myosin II: modulation by G proteins, kinases and myosin phosphatase. Physiol Rev 2003;83:1325-1358.
15. 2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 2003;93:481-483.
16. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol 2004;287:L656-L664.
17. Gonzalez-Luis G, Perez-Vizcaino F, Garcia-Munoz F, de Mey JG, Blanco CE, Villamor E: Age-related differences in vasoconstrictor responses to isoprostanes in piglet pulmonary and mesenteric vascular smooth muscle. Pediatr Res 2005;57:845-852.
18. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-499.
19. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-392.
20. Jourdan KB, Mason NA, Long L, Philips PG, Wilkins MR, Morrell NW: Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. Am J Physiol 2001;280:L1359-L1369.
21. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, Kwapiszewska G, Klepetko W, Seeger W, Olschewski H: Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006;98:1072-1080.
22. Sayner SL, Alexeyev M, Dessauer CW, Stevens T: Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ Res 2006;98:675-681.
23. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA: Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2006;34:242-246.
24. Hoeper MM, Rubin LJ: Update in Pulmonary Hypertension 2005. Am J Respir Crit Care Med 2006;173:499-505.
25. Perkins WJ: Regulation of soluble guanylyl cyclase: looking beyond NO. Am J Physiol 2006;291:L334-L336.
26. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
27. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Circulation 2005;111:3274-3280.
28. Moreno L, Losada L, Cogolludo A, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Pérez-Vizcaíno F: Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors and role on the NO/cyclic GMP pathway. Pediatr Res 2004;56:563-570.
29. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768.
30. Moreno L, Gonzalez-Luis G, Cogolludo A, Lodi F, Lopez-Farre A, Tamargo J, Villamor E, Perez-Vizcaino F: Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am J Physiol 2005;288:L125-L130.
31. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT: Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
32. Ward JP, Robertson TP, Aaronson PI: Capacitative calcium entry: a central role in hypoxic pulmonary vasoconstriction? Am J Physiol 2005;289:L2-L4.
33. Snetkov VA, Aaronson PI, Ward JP, Knock GA, Robertson TP: Capacitative calcium entry as a pulmonary specific vasoconstrictor mechanism in small muscular arteries of the rat. Br J Pharmacol 2003;140:97-106.
34. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JXJ: Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 2004;101:13861-13866.
35. 2+ in pulmonary arterial smooth muscle cells. Circ Res 2006;98:1528-1537.
36. v1.2, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998;101:2319-2330.
37. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98:1400-1406.
38. v1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003;107:2037-2044.
39. + channels in human pulmonary-artery smooth-muscle cells. Lancet 1998;352:290.
40. + channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung 2004;287:L226-L238.
41. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED: Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830-840.
42. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED: Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491.
43. + channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 2004;95:308-318.
44. Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung 2002;283:L839-L848.
45. Villamor E, Perez-Vizcaino F, Cogolludo AL, Conde-Oviedo J, Zaragoza-Arnaez F, Lopez-Lopez JG, Tamargo J: Relaxant effects of carbon monoxide compared with nitric oxide in pulmonary and systemic vessels of newborn piglets. Pediatr Res 2000;48:546-553.
46. Ca channel activity in pulmonary arterial smooth muscle. Am J Physiol 2004;286:L149-L155.
47. Ca channels in rat pulmonary arterial smooth muscle via cGMP-dependent protein kinase. Am J Physiol 2004;286:L1275-L1281.
48. + currents by endothelin-1 in human pulmonary arterial myocytes. Am J Physiol 2001;281:L1115-L1122.
49. + current in rat intrapulmonary arterial myocytes by endothelin-1. Am J Physiol 1998;274:L842-L853.
50. + channels in canine pulmonary artery. Novel mechanism for hypoxia-induced membrane depolarization. Circ Res 1995,77:131-139.
51. Platoshyn O, Brevnova EE, Burg ED, Yu Y, Remillard CV, Yuan JX: Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells. Am J Physiol 2006;290:C907-C916.
52. + channels. Proc Natl Acad Sci USA 1996;93:10489-10494.
53. - channels in cAMP-induced pulmonary vasodilation. Exp Lung Res 1998;24:71-83.